Expert warns of thiazolidinedione-related bone loss in diabetes

08/18/2011 | (free registration)

Following the results of several studies, rheumatologist Dr. Jonathan Graf has cautioned patients with diabetes to avoid using thiazolidinediones as they appear to reduce bone density and elevate fracture risk. However, taking lower doses of thiazolidinediones in combination with either metformin or incretin drugs may still help patients achieve efficient diabetes control without risking bone health, Graf said.

View Full Article in: (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide